Efficacy of 0.05% Cyclosporine A Ophthalmic Emulsion for Pre-existing Dry Eye Disease in Patients Undergoing Pars Plana Vitrectomy: A Randomised Controlled Trial
INTRODUCTION: Evaluation of the efficacy of adjunctive topical 0.05% cyclosporine A (CsA) in patients with pre-existing dry eye disease (DED) undergoing pars plana vitrectomy (PPV). METHODS: This prospective, single‑centre, two-arm randomised controlled trial enrolled 163 adults with pre‑existing DED undergoing PPV. Participants received either 0.05% CsA plus 0.1% sodium hyaluronate or 0.1% sodium hyaluronate alone for 3 months. The primary outcome was the change in Ocular Surface Disease Index (OSDI) score from baseline to 3 months. Secondary outcomes included non‑invasive tear break‑up time (NIBUT), Schirmer I test (SIT), tear meniscus height (TMH) and corneal fluorescein staining (CFS). OSDI, NIBUT, SIT and TMH were analysed using adjusted linear mixed‑effects models, while CFS was analysed using a binomial logistic generalised linear mixed-effects model. RESULTS: All 163 randomised participants (CsA, n = 82; control, n = 81) were included in the longitudinal analyses of ocular surface outcomes using all available repeated measurements. The adjusted between-group difference in OSDI change from baseline to 3 months was -5.29 points (95% confidence interval (CI), -6.53 to -4.05; P < 0.001). A complete-case sensitivity analysis yielded consistent results (-5.19 points; 95% CI, -6.45 to -3.93; P < 0.001). A significant group-by-time interaction was observed for OSDI (P < 0.001). Exploratory analyses of secondary outcomes also showed significant group-by-time interactions for NIBUT (P = 0.002), SIT (P = 0.040), TMH (P < 0.001) and CFS (P = 0.009). CONCLUSIONS: In patients with pre-existing DED undergoing PPV, adjunctive topical 0.05% CsA was associated with modest OSDI improvement and more favourable changes in several objective ocular surface outcomes. Further confirmation in larger, double-masked trials is warranted. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier, ChiCTR2600129992.
Authors
- Dawei Sun (ORCID: https://orcid.org/0000-0002-9717-0190)
- Qiang Hu (ORCID: https://orcid.org/0000-0003-0954-3450)
- Yanan Shen (ORCID: https://orcid.org/0000-0001-8343-6763)
- Xiayu Zhang (ORCID: https://orcid.org/0000-0001-8012-1635)
- Jiajing Zhu
- 浩敏 卢
- Yuege Zhang
- Bo Jiang
- Yi Peng
- Boyu Zhang
Institutions
- Harbin Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1007/s40123-026-01536-5
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bethune Charitable Foundation